BDTX-189 (Synonyms: BDTX-189) |
Catalog No.GC60629 |
BDTX-189 (BDTX-189) es un inhibidor potente, activo por vÍa oral y selectivo de las mutaciones oncogénicas alostéricas de EGFR y HER2, incluidos los mutantes de inserciÓn del exÓn 20 de EGFR/HER2. BDTX-189 muestra KD de 0,2, 0,76, 13 y 1,2 nM para EGFR, HER2, BLK y RIPK2, respectivamente. Actividad anticancerÍgena.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2414572-47-5
Sample solution is provided at 25 µL, 10mM.
BDTX-189 is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, includes EGFR/HER2 exon 20 insertion mutants. BDTX-189 shows KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity[1].
BDTX-189 is a masterKey inhibitor of the ERBB allosteric mutant oncogene family with antiproliferative activity (IC50<100 nM for ERBB allosteric mutant oncogene family)[1].
BDTX-189 (0-100 mg/kg; p.o.; daily for 15 dyas) shows dose-dependent tumor growth inhibition and regression in in athymic nude mice bearing HER2 S310F Ba/F3 allograft tumors[1].BDTX-189 (1-50 mg/kg.p.o.; daily for 15 days) shows dose-dependent tumor growth inhibition and regression in athymic nude mice bearing CUTO-14 PDX tumors that express the EGFR mutation EGFR ASV[1].
[1]. Elizabeth Buck, et al. BDTX-189, a Potent and Selective Inhibitor of Allosteric EGFR and HER2 Oncogenic Mutations.
Average Rating: 5
(Based on Reviews and 9 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *